Zhejiang Tailin Biotechnology Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of the information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
On May 19, 2026, the Company received the inquiry letter from the Shenzhen Stock Exchange (hereinafter referred to as "SZSE") regarding the application to issue convertible bonds to unspecified objects (Inquiry Letter [2026] No. 020044). The SZSE Listing Review Center reviewed the application documents submitted by the Company and formed inquiry questions.